TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Extended Infant Post-exposure Prophylaxis With Antiretrovirals to Reduce Postnatal HIV Transmission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Had given birth within the last 24 hours~* Ability and willingness to give informed consent for HIV testing and enrollment into the study~* Willing to receive HIV results~* HIV infected~* Planning to deliver or had given birth at the study clinics~* Willing to come back for follow-up visits for 2 years postnatally~* Resident of Blantyre city or its suburbs~Exclusion Criteria:~* HIV negative~* Women with discordant HIV results~* Women who indicate that they will not breastfeed at time of delivery~* Inability or unwillingness to follow any of the inclusion requirements~* Newborn with life-threatening condition~* Women who previously enrolled in this study and have a second pregnancy cannot reenroll

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Single dose NVP + ZDV daily for the first week.
- C (Type: EXPERIMENTAL): Arm A plus NVP + ZDV daily to age 14 weeks.
- B (Type: EXPERIMENTAL): Arm A plus oral NVP daily to age 14 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be willing to participate in the study and provide a written informed consent~* Subjects with ABSSSI characterized by any of the following infection types:~  1. Cellulitis/erysipelas: diffuse skin infection characterized by spreading areas of redness, edema, and/or induration~ 2. Wound infection: An infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration~ 3. Major cutaneous abscess: An infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration~* Subjects with lesion size area of at-least 75 cm2. Lesion size will be measured by the area of redness, edema, or induration~* Subjects with suspected and/or documented evidence of Gram-positive infection~Exclusion Criteria:~* 1. ABSSSI meeting any of the following criteria:~  1. Severely impaired arterial blood supply (such that the likelihood of amputation of the infected anatomical site is likely)~ 2. ABSSSI expected to require more than 10 days of antimicrobial therapy as per the discretion of the Investigator~ 3. Subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene~ 4. ABSSSI requiring surgical intervention (except surgical incision and drainage for abscess) 2. Subjects who have received prior antibiotic therapy within past 24 hours for the treatment of current episode of ABSSSI. Following are the exceptions to this criteria:~  <!-- -->~  1. Subjects who received a single dose of a short-acting antibacterial drug within 24 hours of enrolment~ 2. Subjects with evidence of clinical progression of ABSSSI while on antibacterial drug therapy after at-least 48 hours~ 3. Subjects who received an antibacterial drug for surgical prophylaxis and subsequently develop ABSSSI 3. Subjects with current history or diagnosis of HIV, positive test result for hepatitis B surface antigen (HBsAg) or Hepatitis C virus (HCV) 4. Subjects with any clinically significant abnormalities in pulmonary, gastrointestinal, endocrine, hepatic or renal systems

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- levonadifloxacin (Type: EXPERIMENTAL): oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)
- linezolid (Type: ACTIVE_COMPARATOR): oral linezolid (600 mg BID) or IV linezolid (600 mg BID)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 to ≤ 80 years of age~* On an approved statin, with or without ezetimibe, with stable dose(s) for at least 4 weeks~* Fasting LDL-C ≥ 85 mg/dL~* Fasting triglycerides ≤ 400 mg/dL~Exclusion Criteria:~* Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization~* Type 1 diabetes; newly diagnosed or poorly controlled type 2 diabetes (Glycosyated Hemoglobin (HbA1c) \> 8.5%)~* Uncontrolled hypertension~* New York Heart Association (NYHA) III or IV heart failure, or known left ventricular ejection fraction \< 30%~* Uncontrolled cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Q2W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) for 12 weeks.
- Placebo Q4W (Type: PLACEBO_COMPARATOR): Participants received placebo subcutaneous injection once every 4 weeks (Q4W) for 12 weeks.
- Evolocumab 70 mg Q2W (Type: EXPERIMENTAL): Participants received 70 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 105 mg Q2W (Type: EXPERIMENTAL): Participants received 105 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 140 mg Q2W (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks for 12 weeks.
- Evolocumab 280 mg Q4W (Type: EXPERIMENTAL): Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 350 mg Q4W (Type: EXPERIMENTAL): Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.
- Evolocumab 420 mg Q4W (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravenous Allopurinol in Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* The patient is willing and able to provide informed consent~* Clinical diagnosis of chronic heart failure~* Ejection fraction (EF) \< 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography~* No significant coronary disease at cardiac catheterization~* New York Heart Association (NYHA) Class I-IV symptoms~* Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.~Exclusion Criteria:~* Metallic implant prohibiting magnetic resonance (MR) evaluation~* Inability to lie flat for MR study~* Administration of additional investigational drugs~* Calculated creatinine clearance \< 50 mL/min~* Allergy to allopurinol~* Current gout flare~* Currently taking oral allopurinol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allopurinol (Type: EXPERIMENTAL): One time intravenous administration of Allopurinol 300 mg infused over approximately 20 minutes.
- Placebo (Type: PLACEBO_COMPARATOR): One time intravenous administration of 50 ml dose of 5% dextrose infused over approximately 20 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: GORE® Embolic Filter in Carotid Stenting for High Risk Surgical Subjects (EMBOLDEN)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject is either:~   * Symptomatic (amaurosis fugax in the hemisphere supplied by the target vessel, TIA or non-disabling stroke within 6 months of the procedure) with carotid stenosis ≥50% as diagnosed by angiography using NASCET methodology, OR~  * Asymptomatic with carotid stenosis ≥80% as diagnosed by angiography using NASCET methodology~2. Target lesion is located in one of the following:~   * ICA~  * bifurcation~  * CCA proximal to the bifurcation~3. At Anatomic risk for adverse events from CEA (e.g., restenosis after a prior CEA) or at Co-morbid risk for adverse events from CEA (e.g., unstable angina with ECG changes)~Exclusion Criteria:~* Recent surgical procedure within 30 days before or after the stent procedure~* Uncontrolled sensitivity to contrast media~* Renal Insufficiency~* Recent evolving, acute stroke within 21 days of study evaluation~* Myocardial infarction within 72 hours prior to stent procedure~* History of a prior major ipsilateral stroke with residual neurological deficits likely to confound the neurological assessments (e.g., NIHSS)~* Neurological deficits not due to stroke likely to confound the neurological assessments (e.g., NIHSS)~Angiographic Exclusion Criteria:~* Isolated ipsilateral hemisphere leading to subject intolerance to reverse flow~* Total occlusion of the ipsilateral carotid artery~* Pre-existing stent in the ipsilateral carotid artery OR the contralateral carotid artery that extends into the aortic arch~* Presence of a filling defect, thrombus, occlusion or string sign in the target vessel~* Severe lesion calcification restricting stent deployment~* Carotid stenosis located distal to target stenosis that is more severe than target stenosis~* \>50% stenosis of the CCA proximal to target vessel~* Known mobile plaque in the aortic arch

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GORE® Embolic Filter (Type: EXPERIMENTAL): Subjects treated with the GORE® Embolic Filter and an FDA-approved carotid stent.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immune Response to Sars-Covid-19 Vaccines in Haematological Patients: Prospective Single Center Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Signed and dated EC-approved informed consent~* Hematological disease defined according to World Health Organization (WHO) criteria~* Female or male, 18 years of age or older~* ECOG performance status 0-3~* Willingness and ability to comply with routine clinical practice and study procedures~* Regular vaccination against SARS-CoV-2 according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021).~* Routine blood test planned between 30 and 60 days after administration of the second vaccine dose according to regular hematological follow up.~* Routine blood test planned no later than 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies).~Exclusion Criteria:~* Preventive vaccination against SARS-CoV-2 not administered according to Italian Haematological Society (SIE) guidelines/recommendations (Version 2.0, 20 April, 2021)~* Evidence of previous infection with the SARS-Cov-2 virus.~* Routine blood test not planned between 30 and 60 days after administration of the second vaccine dose.~* Routine blood test not planned within 9 months after the completion of the vaccination series (only in case of absence of circulation specific antibodies).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare 2 Formulations of LY900014 in Healthy Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Healthy male or a female (not pregnant and agreeable to take birth control measures until study completion)~* Have a body mass index (BMI) of 18 to 30 kilogram per square meter (kg/m²)~* Have normal blood pressure, pulse rate, electrocardiogram (ECG), blood and urine laboratory test results that are acceptable for the study~* Have veins suitable for easy blood collection and glucose solution infusion~Exclusion Criteria:~- Are currently participating in or completed a clinical trial within the last 30 days or any other type of medical research judged to be incompatible with this study~* Had donated blood of more than 450 milliliters (mL) or participated in a clinical trial with similar blood loss within the last 3 months~* Have a regular alcohol intake greater than 21 units/week (male), or 14 units/week (female)~* Smoke more than 10 cigarettes per day~* Are infected with hepatitis B or human immunodeficiency virus (HIV)~* Are taking illegal drugs

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- LY900014 U-200 (Type: EXPERIMENTAL): Single subcutaneous (SC) dose of LY900014 U-200 in two of four study periods.
- LY900014 U-100 (Type: EXPERIMENTAL): Single SC dose of LY900014 U-100 in two of four study periods.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male or female adults,~* 18 to 50 years of age (21 to 50 years of age for volunteers in Rwanda),~* who do not report high-risk behaviour for HIV infection,~* who are available for the duration of the trial,~* who are willing to undergo HIV testing,~* use an effective method of contraception, and~* who, in the opinion of the principal investigator or designee, understand the study and who provide written informed consent.~Exclusion Criteria:~* confirmed HIV infection,~* pregnancy and lactation,~* significant acute or chronic disease,~* clinically significant laboratory abnormalities,~* recent vaccination or receipt of a blood product,~* previous receipt of an HIV vaccine, and~* previous severe local or systemic reactions to vaccination or history of severe allergic reactions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Group A: SeV-G(NP) followed by Ad35-GRIN (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^7 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
- Group B: SeV-G(NP) followed by Ad35-GRIN (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 followed by Ad35-GRIN (IM) at 1x10\^10 vp at Month 4. (Vaccine/Placebo = 12/4)
- Group C: Ad35-GRIN followed by SeV-G(NP) (Type: EXPERIMENTAL): Ad35-GRIN (IM) at 1x10\^10 vp at Month 0 followed by SeV-G(NP) (IN) at 2x10\^8 CIU at Month 4. (Vaccine/Placebo = 12/4)
- Group D: SeV-G(NP) only (Type: EXPERIMENTAL): SeV-G(NP) (IN) at 2x10\^8 CIU at Month 0 and 4. (Vaccine/Placebo = 12/4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Yoga in Treating Sleep Disturbance in Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of any type of cancer~* More than 1 primary cancer allowed~* Has undergone and completed all forms of standard treatment (surgery, chemotherapy, radiation therapy) within the past 2 to 24 months~* Patients can be on hormones such as Tamoxifen, or monoclonal antibodies like Herceptin~* Persistent sleep disturbance, as indicated by a response of ≥ 3 when asked to rate their sleep on an 11-point scale (0 is equivalent to no sleep disturbance and 10 is the worst possible sleep disturbance)~* Able to read English~* 21 years of age or older~Exclusion Criteria:~* No prior or concurrent regular (≥ 1 day/week) participation in yoga classes or maintain regular personal practice of any form of yoga within the past 3 months~* No diagnosis of sleep apnea~* No concurrent cancer therapy with the exception of hormonal therapy (e.g., tamoxifen citrate) or monoclonal antibodies (e.g., trastuzumab \[Herceptin®\])~* No metastatic cancer

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Yoga Intervention (YOCAS) (Type: EXPERIMENTAL): Standardized Yoga for Cancer Survivors (YOCAS)
- Standard Care Control Condition (Type: EXPERIMENTAL): Standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study on the Feasibility and Acceptability of Pericoital Levonorgestrel 1.5mg

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* between the age of 18-49 years, is willing to use LNG 1.5 mg tablets as her primary contraceptive method, wants to avoid pregnancy for at least the next 6 months after enrollment, is willing to accept an uncertain risk of pregnancy during the study, and understands that the risk of pregnancy on this method would be slightly higher than other methods of contraception~Exclusion Criteria:~* women using one or more of the following contraceptive methods: daily pill, injectable, implant, sterilization

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of Targeted Normoxia in Critically Ill Trauma Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Acute Injury/Trauma~* Arrival to Emergency Department~Exclusion Criteria:~* \<18 years of age~* Known prisoners

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 109 Years
- Healthy Volunteers: f

Study Arms:
- Pre-implementation (Type: None): The control groups will be trauma patients admitted to the ICU 12 months prior to targeted normoxia
- Post-implementation (Type: None): The intervention group will be trauma patients admitted to the ICU during the 6 months after the targeted normoxia implementation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Eszopiclone on the Arousal Threshold in Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-64 years old~* Untreated obstructive sleep apnea~Exclusion Criteria:~* Nadir SaO2 \<70% on a baseline PSG~* Medications known to affect either sleep, breathing or muscle activity~* Major co-morbidities apart from sleep apnea~* Allergy to lidocaine, oxymetazoline HCl, or eszopiclone~* Women who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Eszopiclone (Type: ACTIVE_COMPARATOR): Eszopiclone 3mg prior to sleep (1 night)
- Sugar Pill (Type: PLACEBO_COMPARATOR): Sugar Pill (placebo) prior to sleep (1 night)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient-reported history of Dry Eye Disease in both eyes.~* Use of over the counter artificial tears within the past 30 days.~* A negative urine pregnancy test for females and willingness to use adequate birth control throughout the study.~* Able and willing to comply with all study procedures.~Exclusion Criteria:~* Presence of an ocular condition that could affect the study parameters such as active ocular infections, ocular inflammation, glaucoma, or diabetic retinopathy;.~* Unwilling to stop wearing contact lenses during the study.~* LASIK or other ocular surgical procedures within 12 months prior to or during the study.~* Use of prohibited medications~* Significant medical conditions that could affect the study parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lifitegrast (Type: EXPERIMENTAL): Lifitegrast Ophthalmic Solution 5%, BID for 84 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo to match active treatment, BID for 84 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete